<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01088620</url>
  </required_header>
  <id_info>
    <org_study_id>WISP_AG47</org_study_id>
    <secondary_id>2009-014677-41</secondary_id>
    <secondary_id>GMIHO-006/2008</secondary_id>
    <nct_id>NCT01088620</nct_id>
  </id_info>
  <brief_title>Panitumumab Plus Pemetrexed and Cisplatin (PemCisP) Versus PemCis in the First-line Treatment of Patients With Non-small Cell Lung Cancer</brief_title>
  <official_title>CHAMP - An Open-label, Randomised, Multicentre, Phase II Clinical Study of Panitumumab Plus Pemetrexed and Cisplatin (PemCisP) Versus PemCis in the First-line Treatment of Patients With Stage IIIB or IV Primary Nonsquamous Non-small Cell Lung Cancer, With Particular Regard to the KRAS Status</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>WiSP Wissenschaftlicher Service Pharma GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>WiSP Wissenschaftlicher Service Pharma GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to estimate the therapeutic efficacy of the experimental&#xD;
      targeted regimen including the EGFR antibody panitumumab (in combination with pemetrexed and&#xD;
      cisplatin) in relation to the standard combination in patients with a KRAS wild-type stage&#xD;
      IIIB or IV primary nonsquamous non-small cell lung cancer. It is expected that the&#xD;
      progression free survival rate at 6 months is improved by the targeted regimen.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    the DSMB stopped the trial due to unacceptable side effects in the experimental arm which has&#xD;
    not yet been verified&#xD;
  </why_stopped>
  <start_date>April 2010</start_date>
  <completion_date type="Anticipated">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival rate at 6 months</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determination of the tumour response</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>6 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects / toxicity</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessment</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">134</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>Panitumumab plus pemetrexed and cisplatin (PemCisP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Pemetrexed and cisplatin (PemCis)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Panitumumab</intervention_name>
    <description>Panitumumab 9 mg/kg BW will be administered IV every 3 weeks (q3w) for a maximum of four cycles.&#xD;
In case of CR, PR or SD status at the end of the combination treatment, a panitumumab single drug treatment, consisting of 9 mg/kg BW administered every 3 weeks, will be performed until detection of disease progression.</description>
    <arm_group_label>Panitumumab plus pemetrexed and cisplatin (PemCisP)</arm_group_label>
    <other_name>Vectibix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>Pemetrexed 500 mg/m² will be administered IV every 3 weeks (q3w) for a maximum of four cycles.</description>
    <arm_group_label>Panitumumab plus pemetrexed and cisplatin (PemCisP)</arm_group_label>
    <arm_group_label>Pemetrexed and cisplatin (PemCis)</arm_group_label>
    <other_name>Alimta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin 75 mg/m² will be administered IV every 3 weeks (q3w) for a maximum of four cycles.</description>
    <arm_group_label>Panitumumab plus pemetrexed and cisplatin (PemCisP)</arm_group_label>
    <arm_group_label>Pemetrexed and cisplatin (PemCis)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed diagnosis of inoperable stage IIIB or IV primary pulmonary&#xD;
             nonsquamous NSCLC (according to UICC staging valid until 2008)&#xD;
&#xD;
          -  Sufficient representative sample material for KRAS analysis&#xD;
&#xD;
          -  Wild-type KRAS&#xD;
&#xD;
          -  Informed consent of the patient&#xD;
&#xD;
          -  Aged at least 18 years&#xD;
&#xD;
          -  WHO Performance Status 0-2&#xD;
&#xD;
          -  At least one unidimensional, measurable tumour parameter according to RECIST&#xD;
&#xD;
          -  Life expectancy of al least 12 weeks&#xD;
&#xD;
          -  Adequate haematological, hepatic, renal and metabolic function parameters:&#xD;
&#xD;
               -  Leukocytes &gt; 3000/mm³, ANC ≥ 1500/mm3, platelets ≥ 100,000/mm3, Creatinine&#xD;
                  clearance ≥ 50 ml/min and serum creatinine ≤ 1.5 x upper limit of normal&#xD;
&#xD;
               -  Bilirubin ≤ 1.5 x upper limit of normal, GOT-GPT ≤ 2.5 x upper limit of normal in&#xD;
                  absence of liver metastases, or ≤ 5 x upper limit of normal in presence of liver&#xD;
                  metastases, AP ≤ 5 x upper limit of normal&#xD;
&#xD;
               -  Magnesium ≥ lower limit of normal; calcium ≥ lower limit of normal&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior chemotherapy&#xD;
&#xD;
          -  Clinically manifest, uncontrolled brain metastases&#xD;
&#xD;
          -  Prior radiotherapy of the parameters to be measured&#xD;
&#xD;
          -  Peripheral neuropathy NCI grade &gt; 1&#xD;
&#xD;
          -  Subject pregnant or breast feeding, or planning to become pregnant within 6 months&#xD;
             after the end of treatment.&#xD;
&#xD;
          -  Subject (male or female) is not willing to use highly effective methods of&#xD;
             contraception (per institutional standard) during treatment and for 6 months (male or&#xD;
             female) after the end of treatment (adequate: oral contraceptives, intrauterine device&#xD;
             or barrier method in conjunction with spermicidal jelly).&#xD;
&#xD;
          -  Serious concurrent diseases.&#xD;
&#xD;
          -  Major surgery within the last 4 weeks before recruitment&#xD;
&#xD;
          -  On-treatment participation in a clinical study in the period 30 days prior to&#xD;
             inclusion.&#xD;
&#xD;
          -  Clinically significant cardiovascular disease in (incl. myocardial infarction,&#xD;
             unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac&#xD;
             arrhythmia) ≤ 1 year before enrolment.&#xD;
&#xD;
          -  Ongoing or active infection, including active tuberculosis or known infection with&#xD;
             human immunodeficiency virus.&#xD;
&#xD;
          -  Superior vena cava syndrome contraindicating hydration.&#xD;
&#xD;
          -  History of interstitial lung disease, e.g. pneumonitis or pulmonary fibrosis or&#xD;
             evidence of interstitial lung disease on baseline chest CT scan.&#xD;
&#xD;
          -  Patient with mild to moderate renal insufficiency who are unable to interrupt&#xD;
             salicylates (like aspirin) or other nonsteroidal anti-inflammatory drugs (NSAIDS) for&#xD;
             a 5-day period starting 2 days before administration of pemetrexed (8-day period for&#xD;
             long-acting agents such as piroxicam). Exception: Low dose aspirin (acetyl salicylic&#xD;
             acid) intake up to 150 mg per day is permitted without interruption.&#xD;
&#xD;
          -  Presence of clinically significant third-space fluid collections, for example, ascites&#xD;
             or pleural effusions that cannot be controlled by drainage or other procedures&#xD;
&#xD;
          -  Inability or unwillingness to take folic acid, vitamin B12 supplementation or&#xD;
             dexamethasone (or equivalent corticosteroid); or any other inability to comply with&#xD;
             protocol or study related procedures&#xD;
&#xD;
          -  Prior or concurrent malignancy (≤ 5 years prior to enrolment in study) except&#xD;
             non-melanoma skin cancer or cervical carcinoma FIGO stage 0-1 if the patient is&#xD;
             continuously disease-free&#xD;
&#xD;
          -  Known allergic reactions on study medication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolfgang Schütte, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Krankenhaus Martha-Maria Halle-Dölau</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Schwerpunktpraxis für Hämatologie und Internistische Onkologie, Gesundheitszentrum St. Marien GmbH</name>
      <address>
        <city>Amberg</city>
        <zip>92224</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Charité - Campus Mitte</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Campus Benjamin Franklin Medizinische Klinik m. S. Hämatologie und Onkologie</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HELIOS Klinikum Emil von Behring - Lungenklinik Heckeshorn</name>
      <address>
        <city>Berlin</city>
        <zip>14165</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Augusta-Kranken-Anstalt gGmbH</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johanniter-Krankenhaus Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53113</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carl-Thiem-Klinikum Cottbus gGmbH</name>
      <address>
        <city>Cottbus</city>
        <zip>03048</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Fakultät Carl Gustav Carus der Technischen Universität Dresden Medizinische Klinik 1</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Katholisches Klinikum Duisburg/St. Johannes-Hospital</name>
      <address>
        <city>Duisburg</city>
        <zip>47166</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Frankfurt (Oder) GmbH</name>
      <address>
        <city>Frankfurt (Oder)</city>
        <zip>15236</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Großhansdorf GmbH Onkologischer Schwerpunkt</name>
      <address>
        <city>Großhansdorf</city>
        <zip>22927</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus - Martha-Maria Halle-Dölau GmbH</name>
      <address>
        <city>Halle/Saale</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Halle (Saale), Klinik und Poliklinik für Innere Medizin I</name>
      <address>
        <city>Halle/Saale</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena, Klinik für Innere Medizin I</name>
      <address>
        <city>Jena</city>
        <zip>07740</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis Dr. Stauch</name>
      <address>
        <city>Kronach</city>
        <zip>96317</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken der Stadt Köln, Krankenhaus Merheim</name>
      <address>
        <city>Köln</city>
        <zip>51109</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UK-SH, Campus Lübeck, Med. Klinik III</name>
      <address>
        <city>Lübeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LMU-Klinikum der Universität München, Medizinische Klinik München-Innenstadt</name>
      <address>
        <city>München</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncologianova GmbH</name>
      <address>
        <city>Recklinghausen</city>
        <zip>45657</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinikum Ulm, Klinik für Innere Medizin II, Pneumologie</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <study_first_submitted>March 16, 2010</study_first_submitted>
  <study_first_submitted_qc>March 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2010</study_first_posted>
  <last_update_submitted>March 13, 2013</last_update_submitted>
  <last_update_submitted_qc>March 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <keyword>Stage IIIb or IV</keyword>
  <keyword>Nonsquamous</keyword>
  <keyword>KRAS-Wildtype</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Panitumumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

